Microscale thermophoresis suggests a new model of regulation of cardiac myosin function via interaction with cardiac myosin-binding protein C

Received for publication, September 24, 2021, and in revised form, November 24, 2021 Published, Papers in Press, December 14, 2021, https://doi.org/10.1016/j.jbc.2021.101485

Saraswathi Ponnam and Thomas Kampourakis*
From the Randall Centre for Cell and Molecular Biophysics; and British Heart Foundation Centre of Research Excellence, King’s College London, London, United Kingdom

The cardiac isoform of myosin-binding protein C (cMyBP-C) is a key regulatory protein found in cardiac myofilaments that can control the activation state of both the actin-containing thin and myosin-containing thick filaments. However, in contrast to thin filament–based mechanisms of regulation, the mechanism of myosin-based regulation by cMyBP-C has yet to be defined in detail. To clarify its function in this process, we used microscale thermophoresis to build an extensive interaction map between cMyBP-C and isolated fragments of β-cardiac myosin. We show here that the regulatory N-terminal domains (C0C2) of cMyBP-C interact with both the myosin head (myosin S1) and tail domains (myosin S2) with micromolar affinity via phosphorylation-independent and phosphorylation-dependent interactions of domain C1 and the cardiac-specific m-motif, respectively. Moreover, we show that the interaction sites with the highest affinity between cMyBP-C and myosin S1 are localized to its central domains, which bind myosin with submicromolar affinity. We identified two separate interaction regions in the central C2C4 and C5C7 segments that compete for the same binding site on myosin S1, suggesting that cMyBP-C can crosslink the two myosin heads of a single myosin molecule and thereby stabilize it in the folded OFF state. Phosphorylation of the cardiac-specific m-motif by protein kinase A had no effect on the binding of either the N-terminal or the central segments to the myosin head domain, suggesting this might therefore represent a constitutively bound state of myosin associated with cMyBP-C. Based on our results, we propose a new model of regulation of cardiac myosin function by cMyBP-C.

The cardiac contraction–relaxation cycle is driven by the calcium-dependent interaction of the myosin-containing thick and actin-containing thin filaments. The calcium-induced activation of the thin filaments at the beginning of systole allows myosin head domains from the neighboring thick filaments to strongly attach to actin. Fueled by the hydrolysis of ATP, myosin heads perform the working stroke, leading to nanometer-scale displacement of the thin filaments toward the center of the sarcomere or the development of piconewton-scale forces. Conversely, removal of cytoplasmic calcium ions from the sarcomere deactivates the thin filaments, followed by the detachment of myosin heads from actin and the onset of mechanical relaxation (1).

In addition to the canonical calcium-dependent thin filament–based regulatory pathway described previously, recent studies suggested an additional permissive step during cardiac muscle activation, involving a structural transition in the thick filaments associated with the release of myosin heads from a quasi-helical arrangement on the surface of the thick filaments (OFF or super-relaxed state, SRX) into a functional ON or disordered-relaxed (DRX) state (Fig. 1A) (2, 3). Although no high-resolution structures of the cardiac myosin OFF state are currently available, biochemical and biophysical studies suggest that myosin heads adopt a folded conformation in which their ATPase activity and actin-binding capability are strongly inhibited (4, 5). This folded conformation is characterized by an asymmetric interaction of the two myosin heads of single molecule, with the so-called “free head” sitting on top of the “blocked head” (4, 6, 7). This OFF conformation is believed to be stabilized via myosin head–head and head–tail domain interactions (Fig. 1B) and interaction between the heads and tails with thick filament accessory proteins such as titin and myosin-binding protein C (8–10).

The cardiac isoform of myosin-binding protein C (cMyBP-C) is part of a group of sarcomeric proteins that are frequently found mutated in patients suffering from hypertrophic cardiomyopathy (HCM) associated heart failure, underlining its functional significance in controlling cardiac myofilament function. Moreover, knockout or mutation of cMyBP-C lead to the development of HCM and heart failure in transgenic animal models (11), suggesting that its native structure is required for the normal performance and energy efficiency of the vertebrate heart. Gene knockout of cMyBP-C decreased the calcium sensitivity but accelerated crossbridge kinetics of isolated cardiac muscle (12), indicating that cMyBP-C might have both activating and inhibiting effects on myocardial contractility.

cMyBP-C is composed of interspersed eight immunoglobulin (Ig)-like and three fibronectin-like domains termed C0
The C-terminal regions spanning domains C8 through C10 anchor cMyBP-C to the so-called C-zone, corresponding to the inner two-thirds of the sarcomeric A-band, via interactions with both light meromyosin and titin super-repeats (13, 14). The N-terminal domains (NTDs) C0 and C1 are connected via a proline- and alanine-rich (P/A) linker of about 50 to 60 amino acids, followed by the partially unstructured m-motif linking domains C1 and C2, which contains cardiac-specific phosphorylation sites for physiologically and pathophysiologically relevant protein kinases (15). The NTDs of cMyBP-C have been shown to interact with both the actin-containing thin filaments and myosin-containing thick filaments both in vitro and in situ (16, 17), interactions that are associated with a change in the filament regulatory states. Actin filament binding of NTDs of cMyBP-Cs has been shown to activate the thin filament structure in the absence of Ca\(^{2+}\) (16, 18, 19). This increases the calcium sensitivity of the thin filaments and force generation. In contrast, NTD binding to myosin has been generally associated with a stabilization of the myosin head domain OFF state and reduced contractility (8, 16).

In contrast to the NTD and C-terminal domain, the role of the central segment of cMyBP-C has remained largely elusive, although cardiac-specific sequence insertions and the clustering of missense mutations in the central domains suggest a function beyond a simple spacer that holds the NTDs close to actin-binding and myosin-binding sites (20, 21).

Both the inhibitory and activating effects of the interactions of cMyBP-C are believed to be physiologically controlled by its phosphorylation state. For instance, the effects of \(\beta\)-adrenergic stimulation on cardiac contractile function, such as increased crossbridge kinetics and rate of myofilament relaxation (22), are partially mediated by the protein kinase A (PKA)-dependent phosphorylation of cMyBP-C. Phosphorylation of key sites within the cardiac-specific m-motif is thought to activate the thick filament structure via release of myosin head domains from the filament core into the functional ON or disordered relaxed state, thereby increasing their ATPase activity and the probability for binding to actin (23, 24). In good agreement with the functional studies, HCM-associated mutations in both \(\beta\)-cardiac myosin and cMyBP-C have been shown to interfere with the myosin head OFF state stabilized by cMyBP-C (8, 10). This traps myosin heads in the ON or DRX state (25), which is expected to increase the contractility and energy demand of the myocardium—both hallmarks of HCM. However, the structural basis of the cMyBP-C-based regulation of cardiac myosin function and its impairment during disease states of the heart has remained largely elusive.

In this study, we examined the interaction of the domains of cMyBP-C with several regions of isolated \(\beta\)-cardiac myosin using a quantitative approach via microscale thermophoresis (MST), which allowed us to construct a detailed protein–protein interaction map that includes information on binding parameters. While previous studies solely focused on the phosphorylation-sensitive interaction of the m-motif with myosin S2 (26, 27), we identified the C1/m-motif interface as a phosphorylation-dependent regulatory element that binds close to the myosin head–rod junction.

Moreover, we show that the regulatory interaction sites with the highest affinity between cMyBP-C and the myosin head
domains are not solely localized to the phosphorylatable NTD but also in its central segment. This suggests that the central domains of cMyBP-C are not a passive element that keeps the NTDs near their actin-binding and myosin-binding sites but play a dynamic regulatory role to control the conformation and function of the myosin heads. Thus, we propose a new model of contractile regulation by cMyBP-C that explains the functional effects of cMyBP-C phosphorylation by increasing the probability of its NTDs to bind actin and subsequent release myosin heads from the OFF or SRX state.

Results

Cardiac myosin heads are tightly bound to their tail domains

Here, we probed the interaction of isolated cardiac myosin heads (myosin S1) with their tail domains using MST. Alexa 647-labeled bovine β-cardiac myosin S1 was titrated against increasing concentrations of recombinant human cardiac myosin tail domain, encompassing the first 126 amino acids of myosin subfragment-2 (myosin S2Δ) (Fig. 1C, red). Normalized MST data were fitted to a logistic binding curve, resulting in a steady-state dissociation constant $K_d$ of 0.6 ± 0.1 μm/l (mean ± SEM, n = 8), in good agreement with previously published results using recombinant human β-cardiac myosin head domain (8). As a negative control, we titrated unlabeled myosin S2Δ into Alexa 647-labeled myosin S2Δ, which showed no binding via MST (Fig. 1C, blue).

The local or effective concentrations of both myosin heads and tails in native thick filaments were previously estimated to be in the medium to high micromolar range (8, 17), which is several orders of magnitude higher than the measured $K_d$ value for the head–tail interaction, suggesting that in the absence of other available binding partners one of the two myosin heads of a myosin molecule (i.e., the “blocked head”) is tightly bound to its tail domain. In contrast, the partner head (i.e., the “free head”) is likely less restrained and more mobile.

NTDs of cMyBP-C bind both myosin head and tail domains with moderate affinity

The regulatory N-terminal region of cMyBP-C spanning domains C0 to C2 (C0C2; Fig. 2A) has been shown to interact with cardiac myosin and was proposed to stabilize its OFF state both in vitro and in situ (8, 16, 17). Here, we determined the affinity and interaction specificity of the N-terminal region for the isolated myosin head and tail domains using MST. C0C2 binds the isolated β-cardiac myosin head domain with a $K_d$ of 3.4 ± 0.3 μm/l (mean ± SEM, n = 4) (Fig. 2B, black; Table 1), which is about five times lower than the affinity of myosin S1 for the tail domain. Truncation of domain C2 and the m-motif (i.e., the C0C1 fragment; Fig. 2B, purple) had no significant effect on the interaction with a similar $K_d$ of ~3 μm/l, suggesting that the interaction between myosin S1 and NTD of cMyBP-C is mainly mediated by domain C0, the P/A linker or C1, or a combination thereof.

As a step toward further localizing the myosin S1-binding site, we determined its affinity for individual cMyBP-C domains. Domain C1 binds myosin S1 with a $K_d$ comparable to that of the longer multidomain constructs ($K_d = 3.8 \pm 0.2$ μm/l, mean ± SEM, n = 3), suggesting that the main interaction site between the cMyBP-C NTDs and myosin S1 is localized to domain C1. In agreement, the isolated domains C0, C2, and m-motif showed only weak interaction with myosin S1 with $K_d$ between 40 and 200 μm/l, which is several orders of magnitude lower compared with the binding affinity of either C1 or myosin S2Δ.

In the intact myosin molecule, the regulatory light chains (RLCs) of the two myosin heads form close interactions with each other at the head–tail junction (Fig. 1B), which is believed to be important for the stabilization of the myosin OFF state, and can likely be regulated via phosphorylation of RLC (28). However, an intact RLC neck region is not present in the isolated myosin S1 used in the aforementioned experiments. We therefore produced a recombinant fragment of human cardiac myosin containing the myosin S2Δ tail domain bound to two RLCs, called “miniHMM” (29) (Fig. 2C). The C0C2 fragment binds miniHMM with a $K_d$ of 3.4 ± 0.1 μm/l (mean ± SEM, n = 3), comparable to the binding of C0C2 to myosin S1. A fragment lacking the m-motif and C2 (C0C1) retained binding to miniHMM albeit with about three times lower affinity (10.3 ± 0.5 μm/l; mean ± SEM, n = 3), indicating that either of these domains might contribute to the interaction. As before, we analyzed the contribution of each individual domain to miniHMM binding. Both domain C1 and the m-motif bind miniHMM with a $K_d$ of ~15 and ~50 μm/l (Fig. 2C and Table 1), respectively, localizing the main interaction site to the C1/m-motif interface. Interestingly, the individual domains bind with weaker affinity to miniHMM compared with the larger C0C2 fragment, suggesting a multisite-binding mechanism.

The main interaction site of cMyBP-C with the myosin S2Δ tail was localized to the m-motif (Fig. 2D and Table 1), in very good agreement with previously published results (30). The isolated m-motif binds myosin S2Δ with a $K_d$ of ~40 μm/l, in agreement with m-motif binding to miniHMM. Surprisingly, the affinity of C0C2 for myosin S2Δ ($K_d$ of ~7 μm/l) is about sixfold higher compared with the m-motif alone, although none of the isolated Ig domains show significant binding to the myosin tail, suggesting that the m-motif structure is likely stabilized by the flanking domains. These results are in good agreement with cosedimentation binding assays of C0C2 with isolated cardiac myosin mini filaments (31).

Phosphorylation of C0C2 abolishes interaction with myosin tails but not head domains

Phosphorylation of cMyBP-C in the cardiac-specific m-motif has been associated with a release of myosin head domains from the surface of the thick filament and an increase in myosin crossbridge cycling kinetics (23, 24, 32), suggesting that phosphorylation weakens the interactions between cardiac myosin S1, myosin S2, and cMyBP-C, and thereby favoring actomyosin crossbridge formation.

To test this hypothesis, we in vitro phosphorylated recombinant C0C2 using PKA (Fig. 3A) and isolated the
**Figure 2. Interaction of N-terminal domains of cMyBP-C with cardiac myosin.** A, domain structure and known interaction partners of cMyBP-C. The P/A linker and m-motif (m) are labeled accordingly. B, left, SDS-PAGE and structure of isolated myosin S1 with myosin heavy chain (MHC), essential light chain (ELC), and regulatory light chain (RLC) labeled accordingly. Right, normalized MST binding curves for different cMyBP-C fragments titrated against myosin S1. C, left, SDS-PAGE and structure of miniHMM with myosin tail part (myosin S2Δ) and RLC labeled accordingly. Right, normalized MST binding curves for different cMyBP-C fragments titrated against miniHMM. D, left, SDS-PAGE and structure of myosin S2Δ. Right, normalized MST binding curves for different cMyBP-C fragments titrated against myosin S2Δ. Means ± SEM, n = 3 to 6. cMyBP-C, cardiac isoform of myosin-binding protein C; MST, microscale thermophoresis; P/A, proline- and alanine-rich.
tris-phosphorylated species using ion-exchange chromatography (IEC) as described previously (17). Strikingly, tris-phosphorylation of C0C2 had no effect on its interaction with myosin S1 as indicated by almost identical $K_d$ values (Fig. 3B, left; Table 1). This is consistent with the aforementioned observation that the m-motif has no or little contribution to the C0C2–myosin S1 interaction, which is mainly mediated by domain C1. Similarly, tris-phosphorylated C0C2 (C0C2-3P) retained its interaction with the miniHMM construct, albeit with reduced affinity by about a factor of 3 ($K_d$ of 3.4 ± 0.1 μmol/l versus 9.7 ± 0.5 μmol/l for C0C2 and C0C2-3P, respectively; means ± SEM, n = 3) (Fig. 3B, middle). The decreased affinity of C0C2 for miniHMM after PKA phosphorylation is comparable to the effect of removing the m-motif from C0C2. This suggests that phosphorylation only abolished the interaction between the m-motif and the myosin S2Δ part of miniHMM but has no effect on the C1–miniHMM interaction. Consistent with this hypothesis,

**Table 1**

| cMyBP-C fragment (domain composition) | Myosin S1 | miniHMM | Myosin S2Δ | miniHMM-P |
|--------------------------------------|----------|--------|------------|----------|
| C0C2 (C0-P/A-C1-m-C2)                | 3.4 ± 0.3 | 3.4 ± 0.1 | 6.5 ± 0.6  | 2.7 ± 0.1 |
| C0C2-3P (C0-P/A-C1-m-C2)             | 2.2 ± 0.2 | 9.7 ± 0.5 | cnd        | 5.0 ± 0.1 |
| C0C1 (C0-P/A-C1)                     | 3.8 ± 0.4 | 10.3 ± 0.5 | 199.3 ± 14.3 | cnd     |
| C2C4 (C2–C3–C4)                      | 0.38 ± 0.01 | 4.7 ± 0.3 | 292.4 ± 20.1 | cnd     |
| C5C7 (C5–C6–C7)                      | 0.77 ± 0.1 | 3.2 ± 0.2 | 25.8 ± 0.8  | cnd     |
| C5C7-N755K (C5–C6–C7)                | 0.63 ± 0.04 | — | 73.9 ± 6.9  | cnd     |
| C5C7-R820Q (C5–C6–C7)                | 1.30 ± 0.04 | — | 59.1 ± 2.9  | cnd     |
| C5C7-R943Q (C5–C6–C7)                | 0.61 ± 0.05 | — | 32.6 ± 2.5  | cnd     |
| C2                                  | 91.3 ± 4.5 | 335.1 ± 17.7 | cnd        | cnd     |
| C1                                  | 3.8 ± 0.2 | 17.0 ± 0.5 | cnd        | cnd     |
| C4                                  | 2.5 ± 0.1 | — | cnd        | cnd     |
| C2C4 (C0-P/A-C1-m-C2)                | 0.30 ± 0.02 | 0.51 ± 0.02 | — | — |
| cMyBP-C                             | 0.30 ± 0.02 | 0.51 ± 0.02 | — | — |
| ΔC0C2-cMyBP-C                       | 0.30 ± 0.02 | 0.51 ± 0.02 | — | — |

Means ± SEM (n = 3–7). Abbreviation: cnd, $K_d$ cannot be reliably determined.

Figure 3. Effect of phosphorylation on C0C2–cardiac myosin interactions. A, Phostag-SDS-PAGE of C0C2 before (−) and after in vitro phosphorylation with PKA (+). Individual phosphospecies are clearly separated by Phostag-SDS-PAGE and labeled accordingly. B, normalized MST binding curves for unphosphorylated (C0C2, black) and tris-phosphorylated C0C2 (C0C2-3P, red) titrated against cardiac myosin S1, miniHMM, and myosin S2Δ. C, left, in vitro phosphorylation of miniHMM by cMLCK resolved by Phostag-SDS-PAGE. Right, normalized MST binding curves for C0C2 (black) and C0C2-3P (red) titrated against phospho-miniHMM. D, cartoon representation for the effects of C0C2 phosphorylation on binding to myosin. See main text for details. Means ± SEM, n = 3 to 4. Statistical significance of differences between C0C2 and C0C2-3P was assessed with an unpaired two-tailed Student’s t test: **p < 0.01, *p < 0.05, ns. CD, catalytic domain; cMLCK, cardiac isoform of myosin light chain kinase; C0C2, cMyBP-C spanning domains C0 to C2; ELC, essential light chain; ns, not significant; RLC, regulatory light chain.
cMyBP-C controls cardiac myosin

tris-phosphorylation of C0C2 completely abolishes the interaction with the isolated myosin tail domain (Fig. 3B, right).

However, phosphorylation of not only cMyBP-C but also RLC by the cardiac isoform of myosin light chain kinase (cMLCK) has been associated with an activating effect on the thick filament structure (33, 34) and an increase in force production, calcium sensitivity, and crossbridge kinetics of isolated cardiac muscle (35). Because of the similar structural and functional consequences, we hypothesized that RLC phosphorylation might affect the interaction of cardiac myosin with cMyBP-C.

We in vitro phosphorylated miniHMM using recombinant cMLCK to about 1 mol Pi/mol RLC (Fig. 3 with cMyBP-C. phosphorylation might affect the interaction of cardiac myosin and functional consequences, we hypothesized that RLC isolated cardiac muscle (35). Because of the similar structural production, calcium sensitivity, and crossbridge kinetics of thick (cMLCK) has been associated with an activating effect on the RLC by the cardiac isoform of myosin light chain kinase (346).

High-affinity interaction sites of cMyBP-C with the myosin heads are localized to its central domains

In contrast to the N-terminal and C-terminal domains, the roles of the central region of cMyBP-C are not well understood. However, the majority of HCM-associated missense variants in the gene encoding for cMyBP-C have been localized to its central segment (21), suggesting that the native structure of those domains is necessary for normal cMyBP-C function.

We hypothesized that the central domains of cMyBP-C are involved in its interaction with the myosin heads, and we tested this idea by comparing the binding of full-length and COCC2-truncated cMyBP-C (ΔC0C2-cMyBP-C) to isolated myosin S1 (Fig. 4A). cMyBP-C prepared from Spodoptera frugiperda insect cells (Sf9) has an endogenously low phosphorylation level (Fig. S1). Full-length cMyBP-C binds myosin S1 with a $K_d$ of $0.3 \mu\text{mol/l}$, similar to the affinity of myosin S1 for myosin S2Δ, but about an order magnitude higher than that of the isolated COC2 fragment (Fig. 4A, black; Table 1). Moreover, ΔC0C2-cMyBP-C binds myosin S1 with roughly the same affinity ($K_d$ of $0.5 \mu\text{mol/l}$) (Fig. 4A, red). Taken together, these results suggest the presence of an additional

**Figure 4. The central domains of cMyBP-C tightly bind to the myosin heads.** A, left, SDS-PAGE of purified full length (FL) and COC2-truncated cMyBP-C (ΔC0C2). Right, normalized MST binding curves for full length (FL) (black) and ΔC0C2–cMyBP-C (red) titrated against myosin S1. B, normalized MST binding curves for COC4 titrated against myosin S1 (red), myosin S2Δ (blue), and miniHMM (green). C, normalized MST binding curves for COC7 titrated against myosin S1 (red), myosin S2Δ (blue) and miniHMM (green). D, left, competition model for COC4 and COC7 binding to the same site on myosin S1. Right, competitive titration of COC7 into a mixture of myosin S1 and COC4. The binding curves for COC7 in the absence and presence of COC4 are shown in purple and blue, respectively. The simulated data from the model are shown in the plot as a black dashed line. E, effect of the HCM-associated N755K (blue), R820Q (purple), and R943Q (red) substitutions in COC7 on binding to myosin S1 (left) and myosin S2Δ (right). Means ± SEM, n = 3 to 4. Statistical significance of differences versus wildtype (WT) was assessed with a one-way ANOVA followed by Dunn’s multiple comparison: *p < 0.05, **p < 0.01, and ***p < 0.001. cMyBP-C, cardiac isoform of myosin-binding protein C; COC2, cMyBP-C spanning domains C0 to C2; HCM, hypertrophic cardiomyopathy; MST, microscale thermophoresis.
high-affinity myosin head–binding site in either the central region or the C-terminal region of cMyBP-C. These values are in very good agreement with previously published data using human β-cardiac myosin and the C0C7 region of cMyBP-C lacking the C-terminal anchoring region (K_d of ~1 μmol/l) (10), suggesting that the high-affinity myosin S1-binding site is localized within its central segment.

We analyzed the central domain architecture of cMyBP-C by comparing available high-resolution structures of individual domains and homology models of domains with unknown structure with its primary sequence (Fig. S2). The interdomain linkers between domains C2, C3, and C4 are very short and likely allow tight domain interface interactions, similar to those observed for tandem Ig domains of titin (36). In contrast, the m-motif preceding domain C2 and the longer linker connecting C4 and C5 are likely highly flexible and allow conformational plasticity, consistent with EM images of cMyBP-C showing kinks near both its N-terminal and central regions (37). Biochemical and biophysical characterization of both the individual domains and multidomain constructs suggest that domains in the C2C4 module are in close contact to each other via their loop regions and form a single structural unit (Fig. S3 and Supporting Information text). We tested the C2C4 module for binding to both myosin head and tail domains using MST (Fig. 4B and Table 1). C2C4 binds myosin S1 with a K_d of ~0.4 μmol/l, similar to the binding affinity determined for full length and ΔC0C2-cMyBP-C but did not show any interaction with myosin tails. Moreover, C2C4 binds miniHMM with a K_d of ~5 μmol/l, which corresponds to an about 10-fold lower affinity compared with myosin S1. The comparison suggests that the high-affinity interaction of myosin S1 with C2C4 requires either the essential light chain region or the myosin catalytic domain or both. Notably, the individual domains C2, C3, and C4 bind myosin S1 with a significantly lower affinity (K_d of 3–40 μmol/l; Fig. S4A), indicating that the myosin S1 interaction region is spread across the C2C4 module.

Similarly, domains C5 to C9 are connected via very short linkers, which could facilitate interdomain interactions and reduce the conformational flexibility of this cMyBP-C segment (Fig. S2). Domains C8 to C10 have been shown to tightly interact with both the myosin filament backbone and titin, and EM reconstructions of isolated thick filaments suggested a linear arrangement of these domains on the thick filament surface (4). We therefore tested the remaining domains C5 through C7 (C5C7) for binding to myosin head and tail domains using MST (Fig. 4C and Table 1). Notably, C5C7 binds myosin S1, miniHMM, and myosin S2Δ with K_d of ~0.8, ~3, and ~25 μmol/l, respectively, suggesting that the central region of cMyBP-C exhibits two high-affinity binding regions (i.e., in C2C4 and C5C7) for the myosin head domain. We further confirmed the interactions of C2C4 and C5C7 with the myosin head domains via cosedimentation experiments with artificial cardiac myosin filaments (Fig. S4B).

Two high-affinity binding regions in its central segment suggest that cMyBP-C might be able to simultaneously interact with the two myosin head domains of the same myosin molecule. In order to test this idea, we performed competition experiments and titrated increasing concentrations of C5C7 into a mixture of Alexa647-labeled myosin S1 and C2C4 (Fig. 4D). In the presence of C2C4, the EC_50 for C5C7 binding to myosin S1 increased from ~0.8 to ~3.8 μmol/l, respectively, which is in very good agreement with a simple competition model (Fig. 4C, dashed line), suggesting that C2C4 and C5C7 compete for the same binding region on myosin S1. In contrast to C0C2, the K_d for both C2C4 and C5C7 binding to myosin S1 slightly increased at higher ionic strength, indicating that the interactions at least partially depend on electrostatic interactions (Fig. S5).

Moreover, we tested the binding of the central fragments to isolated bovine native thin filaments (NTFs) using a cosedimentation assay (Fig. S6, A and B). In contrast to the N-terminal fragment C0C2, which binds NTF in saturable manner with a K_d of ~10 μmol/l (38, 39), the central regions C2C4 and C5C7 showed very little or no binding to NTFs, respectively. In very good agreement, both C2C4 and C5C7 had no effect on the NTF-stimulated myosin S1 ATPase activity, whereas C0C2 inhibited the NTF-stimulated myosin S1 ATPase by ~50% in a concentration-dependent manner (Fig. S6C). These results show that the central segment of cMyBP-C (i.e., C2C7) does not interact with the thin filament, which is in stark contrast to its strong binding to myosin S1.

HCM-associated nontruncating missense variants in cMyBP-C have been found to cluster in its central segment (21, 40), and we hypothesized that these mutations might affect the interaction of the central domains of cMyBP-Cs with cardiac myosin. To test this hypothesis, we generated C5C7 constructs carrying either the N755K, R820Q, or R943Q substitution in domains C5, C6, and C7, respectively. Homology modeling of domains suggests that all residues are surface accessible and likely do not affect protein folding, in good agreement with the soluble expression profile of these constructs in bacterial cultures (Fig. S7). Although both the N755K and R820Q substitutions only showed a small but significant effect on the interaction of C5C7 with myosin S1 (K_d of ~0.7 μmol/l for wildtype versus K_d of ~0.4 and ~1.3 μmol/l for N755K and R820Q, respectively) (Fig. 4E, left), both variants strongly decreased the affinity for myosin S2Δ as indicated by K_d values about 2 to 3 times larger than those observed for the wildtype protein (Fig. 4E, right). In contrast, the R943Q variant did not show an effect on binding to either myosin S1 or myosin S2Δ. These results support the hypothesis that HCM-associated mutations in this region of cMyBP-C at least partially exert their pathological effect via altered interactions with cardiac myosin.

**Discussion**

**The central domains of cMyBP-C tightly bind to the myosin motors**

Although the structural effects of cMyBP-C binding to and activating the actin-containing thin filaments have been extensively studied (18, 19, 41, 42), the structural basis of the functional effect of cMyBP-C on the thick filament structure
cMyBP-C controls cardiac myosin

has remained largely elusive. Early studies suggested that the m-motif binds myosin S2 in a phosphorylation-sensitive manner (26), which would allow control of the myosin head orientation and therefore actomyosin-driven contractility via phosphorylation of cMyBP-C. More recent studies, however, have suggested a more complicated effect of NTD of cMyBP-C on the regulatory state of thick filament mediated by direct interactions with the force-generating myosin head domains (8, 10, 29).

Although our results agree with the hypothesis that NTD of cMyBP-C acts as a phosphorylation-sensitive regulatory element that binds to both the myosin head and tail domains, several independent lines of evidence suggest that the interaction sites with the highest affinity between cMyBP-C and myosin are not localized to its NTD (Fig. 4F). First, the binding affinity of full-length cMyBP-C to myosin S1 is about an order of magnitude higher compared with the isolated C0C2 fragment. Second, removal of the C0C2 region from cMyBP-C had only a small effect on the binding affinity to myosin S1. Third, fragments of the central segment of cMyBP-Cs bind myosin S1 with about the same affinity as the full-length protein.

The present results therefore indicate that the interaction sites with the highest affinity between cMyBP-C and myosin S1 are localized to the central segment of cMyBP-C. Comparison of the primary sequence of the central segment of cMyBP-C with available high-resolution structures and homology models of individual domains shows a defined modular architecture with regions of low interdomain flexibility. Domains C2, C3, and C4 are connected via short three amino-acid linkers, which would allow close domain–domain interactions via their proximal loop regions. Biochemical and biophysical characterization of this region is in good agreement with a rigid arrangement of these domains, which is further supported by published small-angle X-ray scattering data on the C2C4 and C3C4 module, showing low conformational flexibility (43). A similar domain architecture was observed for the C5C7 module, although with some flexibility between C5 and C6 (43, 44).

Both C2C4 and C5C7 bind myosin S1 with about the same affinity as the full-length and C0C2-truncated cMyBP-C, indicating that the central segment of cMyBP-C has two independent high-affinity myosin S1-binding regions. Moreover, direct competition between C2C4 and C5C7 for myosin S1 binding indicates overlapping interaction sites on the myosin head domain as shown by MST (Fig. 4C). In the sarcomeric C-zone, three molecules of cMyBP-C are associated with three pairs of myosin heads out of the nine pairs in every 43 nm repeat (45). The stoichiometry and overlapping binding sites for myosin S1 suggests that a single cMyBP-C molecule can simultaneously interact with the two myosin heads of an individual myosin molecule. The central segment of cMyBP-C might therefore be directly involved in the stabilization of the myosin filament OFF state by crosslinking the so-called “blocked” and “free” head and stabilize the interacting-heads motif (IHM). Moreover, the C-terminal anchoring region (C8C10) of cMyBP-C has been associated with the free head of the proceeding myosin head pair (4), suggesting that cMyBP-C might also be able to crosslink myosin heads on adjacent crowns and facilitate intermolecular signaling between myosin molecules within the thick filament. The presence of multiple myosin-binding regions might also explain how cMyBP-C can control the conformation of the majority of myosin heads in the C-zone despite its low stoichiometry compared with myosin heads.

Taken together, these results suggest that the central region of cMyBP-C is not a passive scaffold that holds the NTDs in close proximity to the myosin head domains or actin as currently thought (46) but likely constitutes a dynamic regulatory element that contributes to the regulation of the activation state of myosin in the thick filament, the availability of myosin heads for contraction, and the associated ATP utilization. Notably, according to these results, cMyBP-C does not lie parallel to the thick filament axis in an extended conformation as previously thought, but its N-terminal and central domains are likely organized into a more compact docking platform. Although many structural details of these interactions remain unclear, their effect is to stabilize a population of myosin heads in a roughly helical lattice on the surface of the thick filaments, that is, the myosin OFF or IHM state observed in EM reconstructions of isolated thick filaments.

These results help to explain the etiology of heart failure associated with HCM-linked mutations in this region of cMyBP-C, which might interfere with myosin interaction and dysregulate the thick filament by increasing the number of myosin head domains in the functional ON state (Fig. 4D). Mutations might increase the energy demand of the heart and cause a hypercontractile phenotype—both hallmarks of HCM. In good agreement, nontruncating missense mutations appeared to cluster in the C3, C6, and C10 domains, which suggest that these domains are key regions for the native function of the protein (40).

Potential role of the cardiac-specific C0 domain

The conserved structural features between the cardiac and skeletal muscle isoforms of MyBP-C suggest a similar mode of interaction between skeletal MyBP-C and skeletal muscle myosin. However, cardiac MyBP-C exhibits unique structural features, including an additional N-terminal Ig-like domain termed C0, with unknown functional significance.

The current experiments only show a weak interaction of C0 with cardiac myosin in vitro. However, the local or effective concentrations of both myosin and cMyBP-C were estimated to be in the high micromolar range, which would make a \( K_d \) of \(~90\ \mu M\) for myosin S1 binding functionally significant. A previous study suggested an interaction with the RLC region of myosin with \( K_d \) in the low micromolar range (29).

In contrast, C0 has been shown to readily interact with bare F-actin and isolated NTFs with low micromolar \( K_d \) in a position that does not interfere with tropomyosin’s position on F-actin (19, 41). Moreover, binding of C0 to isolated NTFs has been proposed to enhance binding of domain C1, which
competes for tropomyosin-binding sites on actin and can activate the thin filament structure in the absence of calcium.

Domains C0 and C1 are connected via a largely unstructured P/A-rich linker of 50 to 60 amino acid residues. The P/A linker is highly flexible and mobile in solution and can adopt both a folded and an extended conformation with a maximal extension of ~8 nm (43). The maximally extended conformation would allow C0-P/A/-C1 alone to bridge the interfilament distance with a maximal length of ~18 nm, significantly longer than the estimated surface-to-surface distance of thick and thin filaments in the intact myofilament lattice (~15 nm) (47).

This suggests that although the domains C1 through C10 are bound to the surface of the thick filament via strong interactions with the filament backbone, and myosin head and tail domains, the NTD C0 can reach the actin-containing thin filament in the presence of the myosin filament OFF state (Fig. 5A). This might constitute a cardiac-specific interfilament signaling pathway that can coordinate the regulatory state of the thin and thick filaments during cardiac muscle activation.

Moreover, it was previously suggested that the P/A linker might act as a spring-like element, which shares high sequence homology to the proline-, glutamate-, valine-, and lysine-rich region of titin (48). The amino acid composition and length of the P/A linker correlates with the heart rate of mammals (49) and can be phosphorylated by physiologically relevant kinases such as glycogen synthase kinase 3-β (50), suggesting that the flexibility and length of the P/A linker and therefore thin filament binding of C0 can be tuned to a specific functional task of the heart muscle.

**Effects of cMyBP-C and myosin RLC phosphorylation**

Although phosphorylation of cMyBP-C has important functional consequences for the myocardium, such as increased crossbridge kinetics and decreased myofilament calcium sensitivity, and is essential for the normal performance of the mammalian heart (51), phosphorylation of NTD of cMyBP-C had either no or small effects of its interaction with myosin. The only phosphorylation-sensitive interaction was observed between the cardiac-specific m-motif and myosin S2A. In contrast, COC2 phosphorylation had no effect on the binding to myosin S1 and only weakened the interaction with miniHMM.

Moreover, the interaction of the central domains of cMyBP-C with myosin S1 are likely phosphorylation independent and might represent a constitutively bound state of the myosin motors, suggesting that phosphorylation does not abolish myosin–cMyBP-C interactions per se as currently thought (8, 26) but rather changes the conformation of the cMyBP-C–myosin head complex, which likely facilitates interaction of both the N-terminus of cMyBP-C and myosin heads with actin. For instance, the central segments C2C4 and C5C7 might compete with COC2 for binding sites on miniHMM in a phosphorylation-sensitive manner, which might allow myosin heads to leave the folded OFF state upon phosphorylation of m-motif of cMyBP-C.

Similarly, RLC phosphorylation did not change the interaction of miniHMM with COC2, supporting the idea that RLC and cMyBP-C phosphorylation independently regulate myofilament function. cMyBP-C and RLC are phosphorylated by different kinases operating downstream of distinct signaling pathways. Moreover, RLC phosphorylation is likely to affect the regulatory state of the myosin heads in the whole thick filament, whereas the effects of cMyBP-C phosphorylation are restricted to every third crown of myosin heads in the sarcomeric C-zone, although its regulatory effects can likely be communicated between myosin molecules via cooperative transitions in the thick filament structure implied by interaction between successive myosin heads in the thick filament.

**Figure 5. Hypothetical model for the role of cMyBP-C during cardiac muscle activation.** A, in the dephosphorylated state, cMyBP-C (dark gray) is bound to myosin catalytic domains of the myosin blocked head (red) and free head (purple) via interactions of its central domains (C2C4 and C5C7, respectively) and C1/m-motif with the RLC-neck region. The N-terminal domain C0 is in a conformational equilibrium between thin filament bound and unbound states, determined by the flexibility and elongation of the P/A linker. B, phosphorylation (yellow circles) of cMyBP-C abolishes the m-motif–myosin S2 interaction, which releases parts of cMyBP-C (and associated myosin heads) from the thick filament backbone, and increases the probability of C0–thin filament interactions. C, calcium activation of the thin filaments subsequently leads to cMyBP-C domain C1 cooperatively binding to available actin-binding sites in proximity to C0, which would fully activate the thin filament. In addition, this structural rearrangement would bring cMyBP-C–attached myosin heads closer to the surface of the calcium-activated thin filament and increase the probability of actomyosin crossbridge formation. cMyBP-C, cardiac isoform of myosin-binding protein C; P/A, proline and alanine-rich.
OFF state (Fig. 4E) (4). In good agreement, RLC phosphorylation increases both the calcium sensitivity of isometric force and the rate of force redevelopment of rat ventricular trabeculae by roughly the same extent independent of the cMyBP-C phosphorylation background (28, 52, 53).

**Hypothetical model of cardiac myosin regulation by cMyBP-C**

Our results are consistent with a hypothetical model in which cMyBP-C stays tightly associated with the myosin head domains during both the diastolic and systolic states of the myocardium mediated by the phosphorylation-sensitive interactions of the NTDs of cMyBP-C with the myosin neck/tail region and its central domains with the myosin heads.

The aforementioned results in combination with the studies cited in the introduction lead to a new working model for cardiac myosin regulation by cMyBP-C. In the diastolic OFF state, myosin heads are sequestered in the IHM via head–tail interactions, and myosin heads in the C-zone are further tethered to the surface of the thick filament via strong interactions of C-terminal domains (C8C10) of cMyBP-C with the filament backbone and its central region (C5C7 and C2C4) with the free head and blocked head of the succeeding myosin molecule, respectively. The OFF state is further stabilized via interactions of the m-motif and C1 domain with the myosin tail and head domains, respectively. In contrast, domain C0 is in a dynamic equilibrium between thin filament bound and unbound states, which is facilitated by the high flexibility and mobility of the P/A linker (Fig. 5A).

PKA phosphorylation of the m-motif during β-adrenergic stimulation abolishes its interaction with the myosin tail domain and weakens the interaction of NTD of cMyBP-C with the myosin neck region (Fig. 5B). Moreover, phosphorylation changes the structure of the NTD from an elongated to a more compact conformation and increases the mechanical stability of the m-motif (37, 54). This combined structural rearrangement brings both domains C0 and C1 closer to the surface of the thin filament (Fig. 5B). Since both domains have been shown to cooperatively bind to the thin filament, this would increase the probability of thin filament interactions of domain C1 (Fig. 5B, double arrow), which has been shown to have an activating effect on the thin filament structure by competing with tropomyosin for actin-binding sites (19). Because myosin heads strongly interact with the C2C4 segment, this structural rearrangement would bring the myosin catalytic domain of the free head closer to the surface of the thin filament.

Increase in the intracellular calcium concentration at the beginning of systole would subsequently trigger the activation of the remainder of the thin filament and allow NTDs of cMyBP-C and cMyBP-C-bound myosin motors to strongly attach to actin (Fig. 5C). Phosphorylation of m-motif of cMyBP-C would therefore favor actomyosin interactions by bringing myosin head domains tethered to the central segment of cMyBP-C closer to the surface of the thin filament, consistent with X-ray diffraction experiments on isolated cardiac muscle and electron micrographs of isolated thick filaments carrying constitutively phosphorylated cMyBP-C (24, 32). Conversely, at the end of systole, when the calcium transient has already reached diastolic levels, myosin heads associated with cMyBP-C would remain attached to actin because of cMyBP-C locally stabilizing the thin filament ON state (3, 16) and increasing the effective concentration of the myosin heads close to their actin-binding sites.

In this view of regulation, cMyBP-C directly controls the rate of myosin crossbridge attachment and detachment from actin via guiding myosin heads from the folded IHM OFF state into the actin-attached ON state and vice versa. The results described previously establish a new model for myosin-based regulation by cMyBP-C, its physiological control via phosphorylation, and impairment associated with heart disease and heart failure.

**Experimental procedures**

**Protein production**

Bovine β-cardiac myosin S1 was prepared from freshly frozen bovine heart ventricle as described previously (55). Alternatively, bovine β-cardiac myosin S1 was purchased from Cytoskeleton, Inc.

MiniHMM was expressed from a pET Duet-1 vector in BL21(DE3)-RIPL cells (Agilent Technologies; catalog no.: 230240) and purified by affinity chromatography on HisTrapFF columns (GE Healthcare). Histidine tag was removed by digestion with tobacco etch virus (TEV) protease, and the histidine tag and TEV protease removed by passing the digestion mixture through a 1 ml HisTrapFF column and collecting the flow through.

Myosin S2Δ, miniHMM, and cMyBP-C constructs were prepared as described previously (30). Briefly, proteins were expressed from a modified pET6a vector fused to an N-terminal histidine tag and TEV protease site in BL21(DE3)-RIPL cells. Following purification on HisTrapFF columns, the histidine tags were removed by treatment with TEV protease. Proteins were further purified by IEC on Mono S or Mono Q columns (GE Healthcare), concentrated to >100 μmol/l, snap-frozen in liquid nitrogen, and stored in aliquots at −80 °C for experiments. Purity was estimated by SDS-PAGE and electrospray ionization MS (ESI–MS) to >95%.

Full-length and COC2-truncated cMyBP-C were expressed in S. frugiperda (Sf9) cells according to the manufacturer’s instructions (Thermo Fisher Scientific) and purified by affinity chromatography on HisTrapFF columns followed by TEV digest of the N-terminal histidine tag and size-exclusion chromatography on Superose12 columns.

**Differential scanning fluorimetry**

Proteins were mixed with 20× SYPRO Orange (Thermo Fisher Scientific) in PBS containing 1 mmol/l DTT, dispensed in a BioRad qPCR plate, and heated from 25 to 95 °C at a rate of 1 °C/min in a MX3005p qPCR machine (Agilent). Fluorescent emission at 610 nm following excitation at 492 nm was measured, with the resulting curve defined in Excel, and the $T_m$ was calculated in GraphPad Prism (GraphPad Software, Inc).
Fluorescence spectroscopy

Fluorescence emission spectra were recorded on FluoroMax Spectrofluorometer. Emission spectra were recorded with 1 nm excitation and emission filter slit and corrected for background fluorescence.

Protein phosphorylation

Recombinant COC2 was phosphorylated by incubation with the catalytic subunit of PKA (Calbiochem) and the tris-phosphorylated species was purified by IEC as described previously (17). MiniHMM was phosphorylated using the catalytic subunit of human cMLCK as described previously for isolated RLC (33). Phosphate incorporation and purity of phosphoproteins were estimated by Phostag-SDS-PAGE and ESI–MS.

MST

MST experiments were performed on a Monolith NT.115 instrument (NanoTemper) in interaction buffer containing 20 mmol/l Mops, pH 7, 1 mmol/l MgCl2, 50 mmol/l KCl, 1 mmol/l DTT, and 0.05% (v/v) Tween-20. For experiments with the isolated m-motif, the pH was adjusted to 6.2.

Proteins were labeled with Alexa 647-NHS (Molecular Probes, Inc; Thermo Fisher Scientific) according to the manufacturer’s instructions, and dye incorporation (efficiency of >80%) was confirmed by HPLC and ESI–MS. All proteins were either gel-filtered into and/or extensively dialyzed against interaction buffer. Titration experiments were performed with a fixed concentration of 100 nmol/l of Alexa647-labeled proteins in premium capillaries.

NTF cosedimentation

NTFs were prepared according to previously published protocols, and cosedimentation experiments were performed as described (38).

Myosin filament cosedimentation

Bovine cardiac myosin was prepared according to previously published protocols, and cosedimentation experiments were performed as described (31).

Models of cMyBP-C domains and protein docking

Structures of cMyBP-C domains were generated in SWISS-MODEL (56) and energy minimized using ModRefiner (57).

Statistical analysis

Data are represented as means ± SEM, with the number of experiments indicated by n. Statistical significance of the difference between two groups was assessed with an unpaired two-tailed Student’s t test. Details of significance levels are shown in the figure legends.

Data availability

The data supporting the findings of the study are available in the article and its Supporting Information. All remaining raw data will be available from the corresponding author upon reasonable request.

Supporting information—This article contains supporting information.

Acknowledgments—We thank Elisabeth Ehler, Malcolm Irving, Ivanka Sevrieva, and Mathias Gautel for help and support and critical reading of the article. We thank Mark Pfuhl for kindly providing the miniHMM expression construct.

Author contributions—T. K. conceptualization; T. K. methodology; T. K. and S. P. formal analysis; T. K. and S. P. investigation; T. K. and S. P. data curation; T. K. writing—original draft; T. K. visualization; T. K. supervision; T. K. project administration; T. K. funding acquisition.

Funding and additional information—We thank the British Heart Foundation for financial support (FS/16/3/31887 to T. K.).

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: cMLCK, cardiac isoform of myosin light chain kinase; cMyBP-C, cardiac isoform of myosin-binding protein C; COC2, CmyBP-C spanning domains C0 to C2; C0C2-3P, Tris-phosphorylated COC2; ESI, electrospray ionization; HCM, hypertrophic cardiomyopathy; Ig, immunoglobulin; IHM, interacting-heads motif; MST, microscale thermophoresis; myosin S2Δ, myosin subfragment-2; NTD, N-terminal domain; NTF, native thin filament; P/A, proline- and alanine-rich; PKA, protein kinase A; RLC, regulatory light chain; TEV, tobacco etch virus.

References

1. Gordon, A. M., Homsher, E., and Regnier, M. (2000) Regulation of contraction in striated muscle. Physiol. Rev. 80, 853–924
2. Linari, M., Brunello, E., Reconditi, M., Fusi, L., Caremani, M., Narayanan, T., Piazzesi, G., Lombardi, V., and Irving, M. (2015) Force generation by skeletal muscle is controlled by mechanosensing in myosin filaments. Nature 528, 276–279
3. Brunello, E., Fusi, L., Ghisleni, A., Park-Holohan, S. J., Ovejero, J. G., Narayanan, T., and Irving, M. (2020) Myosin filament-based regulation of the dynamics of contraction in heart muscle. Proc. Natl. Acad. Sci. U. S. A. 117, 8177–8186
4. Al-Khayat, H. A., Kensler, R. W., Squire, J. M., Marston, S. B., and Morris, E. P. (2013) Atomic model of the human cardiac muscle myosin filament. Proc. Natl. Acad. Sci. U. S. A. 110, 318–323
5. Alonso, L., Ware, J. S., Pinto, A., Gillilan, R. E., Seidman, J. G., Seidman, C. E., and Padron, R. (2017) Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes. Elife 6, e24634
6. Wendt, T., Taylor, D., Trybus, K. M., and Taylor, K. (2001) Three-dimensional image reconstruction of dephosphorylated smooth muscle heavy meromyosin reveals asymmetry in the interaction between myosin heads and placement of subfragment 2. Proc. Natl. Acad. Sci. U. S. A. 98, 4361–4366
7. Woodhead, J. L., Zhao, F. Q., Craig, R., Egelman, E. H., Alamo, L., and Padron, R. (2005) Atomic model of a myosin filament in the relaxed state. Nature 436, 1195–1199
8. Nag, S., Trivedi, D. V., Sarkar, S. S., Adhikari, A. S., Sunita, M. S., Sutton, S., Ruppel, K. M., and Spudich, J. A. (2017) The myosin mesa and...
the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations. Nat. Struct. Mol. Biol. 24, 525–533

9. Adhikari, A. S., Trivedi, D. V., Sarkar, S. S., Song, D., Kooiker, K. B., Bernstein, D., Spudich, J. A., and Ruppel, K. M. (2019) beta-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity. Nat. Commun. 10, 2685

10. Sarkar, S. S., Trivedi, D. V., Morck, M. M., Adhikari, A. S., Pasha, S. N., Ruppel, K. M., and Spudich, J. A. (2020) The hypertrophic cardiomyopathy mutations R403Q and R663H increase the number of myosin heads available to interact with actin. Sci. Adv. 6, eaaax0069

11. Harris, S. P., Bartley, C. R., Hacker, T. A., McDonald, K. S., Douglas, P. S., Greaser, M. L., Powers, P. A., and Moss, R. L. (2002) Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice. Circ. Res. 90, 594–601

12. Korte, F. S., McDonald, K. S., Harris, S. P., and Moss, R. L. (2003) Loaded skeletal muscle thick filament activation in cardiac myosin binding protein C (MysBP-C, C-protein) specifies incorporation into the A-band of striated muscle. J. Cell Sci. 109, 101–111

13. Gilbert, R., Kelly, M. G., Mikawa, T., and Fischman, D. A. (1996) The carboxyl terminus of myosin binding protein C (MyBP-C, C-protein) specifies incorporation into the A-band of striated muscle. J. Cell Sci. 109, 317–323

14. Freiburg, A., and Gautel, M. (1996) A molecular map of the interactions between titin and myosin-binding protein C. Implications for sarcomere assembly in familial hypertrophic cardiomyopathy. Eur. J. Biochem. 235, 317–323

15. Bardswell, S. C., Cuello, F., Kentsh, J. C., and Avkiran, M. (2012) cMyBP-C as a promiscuous substrate: phosphorylation by non-PKA kinases and its potential significance. J. Muscle Res. Cell Motil. 33, 53–60

16. Kampourakis, T., Yan, Z., Gautel, M., Sun, Y. B., and Irving, M. (2014) Myosin binding protein C activates thin filaments and inhibits thick filaments in heart muscle cells. Proc. Natl. Acad. Sci. U. S. A. 111, 18763–18768

17. Ponnam, S., Sevrieva, I., Sun, Y. B., Irving, M., and Kampourakis, T. (2019) Site-specific phosphorylation of myosin binding protein C coordinates thin and thick filament activation in cardiac muscle. Proc. Natl. Acad. Sci. U. S. A. 116, 15485–15494

18. Mun, J. Y., Previs, M. I., Yu, H. Y., Gulick, J., Tobacman, L. S., Beck Previs, S., Robbins, J., Warshaw, D. M., and Craig, R. (2014) Myosin-binding protein C displaces tropomyosin to activate cardiac thin filaments and governs their speed by an independent mechanism. Proc. Natl. Acad. Sci. U. S. A. 111, 2170–2175

19. Harris, S. P., Belknap, B., Van Sciver, R. E., and Galkin, V. E. (2018) N-terminal domains of cardiac myosin binding protein C with myosin-S2 in an on-off fashion. FEBS Lett. 543, 254–259

20. Bhuiyan, M. S., Gulick, J., Osinska, H., Gupta, M., and Robbins, J. (2012) Determination of the critical residues responsible for cardiac myosin binding protein C’s interactions. J. Mol. Cell Cardiol. 53, 838–847

21. Kampourakis, T., Sun, Y. B., and Irving, M. (2016) Myosin light chain phosphorylation enhances contraction of heart muscle via structural changes in both thick and thin filaments. Proc. Natl. Acad. Sci. U. S. A. 113, E3039–E3047

22. Ratti, J., Rostkova, E., Gautel, M., and Pfuhl, M. (2011) Structure and interactions of myosin-binding protein C domain Cb: Cardiogenic-specific regulation of myosin at its neck? J. Biol. Chem. 286, 12650–12658

23. Kampourakis, T., Ponnam, S., Sun, Y. B., Sevrieva, I., and Irving, M. (2018) Structural and functional effects of myosin binding protein C phosphorylation in heart muscle are not mimicked by serine-to- aspartate substitutions. J. Biol. Chem. 293, 14270–14275

24. Bunch, T. A., Lepak, V. C., Kanassatega, R. S., and Colson, B. A. (2018) N-terminal extension in cardiac myosin-binding protein C regulates myofilament binding. J. Mol. Cell Cardiol. 125, 140–148

25. Colson, B. A., Bekyarova, T., Lencer, M. R., Fitzsimons, D. P., Irving, T. C., and Moss, R. L. (2008) Protein kinase A-mediated phosphorylation of cMyBP-C increases proximity of myosin heads to actin in resting myocardium. Circ. Res. 103, 244–251

26. Kampourakis, T., and Irving, M. (2015) Phosphorylation of myosin regulatory light chain controls myosin head conformation in cardiac muscle. J. Mol. Cell Cardiol. 85, 199–206

27. Levine, R. J., Kentsler, R. W., Yang, Z., Stull, J. T., and Sweeney, H. L. (1996) Myosin light chain phosphorylation affects the structure of rabbit skeletal muscle thick filaments. Biophys. J. 71, 899–907

28. Olsson, M. C., Patel, J. R., Fitzsimons, D. P., Walker, J. W., and Moss, R. L. (2004) Basal myosin light chain phosphorylation is a determinant of Ca2+ sensitivity of force and activation dependence of the kinetics of myocardial force development. Am. J. Physiol. Heart Circ. Physiol. 287, H2712–H2718

29. von Castelmur, E., Marino, M., Svergun, D. I., Kreplak, L., Ucurum-Fotiadis, Z., Konarev, P. V., Urzhumtsev, A., Labeit, D., Labeit, S., and Mayans, O. (2008) A regular pattern of Ig super-motifs defines segmental flexibility as the elastic mechanism of the titin chain. Proc. Natl. Acad. Sci. U. S. A. 105, 1186–1191

30. Previs, M. J., Mun, J. Y., Michealek, A. J., Previs, S. B., Gulick, J., Robbins, J., Warshaw, D. M., and Craig, R. (2016) Phosphorylation and calcium antagonistically tune myosin-binding protein C’s structure and function. Proc. Natl. Acad. Sci. U. S. A. 113, 3239–3244

31. Shaffer, J. F., Kentsler, R. W., and Harris, S. P. (2009) The myosin-binding protein C motif binds F-actin in a phosphorylation-sensitive manner. J. Biol. Chem. 284, 12318–12327

32. Bunch, T. A., Kanassatega, R. S., Lepak, V. C., and Colson, B. A. (2019) Human cardiac myosin-binding protein C restricts actin structural dynamics in a cooperative and phosphorylation-sensitive manner. J. Biol. Chem. 294, 16228–16240

33. Helms, A. S., Thompson, A. D., Glazier, A. A., Hafeez, N., Kabani, S., Rodriguez, J., Yob, J. M., Woolcock, H., Mazzarotto, F., Lakdawala, N. K., Wittekind, S. G., Pereira, A. C., Jacoby, D. L., Colan, S. D., Ashley, E. A., et al. (2020) Spatial and functional distribution of MYBPC3 pathogenic variants and clinical outcomes in patients with hypertrophic cardiomyopathy. Circ. Genom. Precis. Med. 13, 396–405

34. Risi, C., Belknap, B., Forgacs-Lonart, E., Harris, S. P., Schroder, G. F., White, H. D., and Galkin, V. E. (2018) N-terminal domains of cardiac myosin binding protein C cooperatively activate the thin filament. Structure 26, 1604–1611

35. Inchingolo, A. V., Previs, S. B., Previs, M. J., Warshaw, D. M., and Kad, N. M. (2019) Revealing the mechanism of how cardiac myosin-binding protein C N-terminal fragments sensitize thin filaments for myosin binding. Proc. Natl. Acad. Sci. U. S. A. 116, 6828–6835

Ablation of cardiac myosin binding protein-C disrupts the super-structured state of myosin in murine cardiomyocytes. J. Mol. Cell Cardiol. 94, 65–71
43. Jeffries, C. M., Lu, Y., Hynson, R. M., Taylor, J. E., Ballesteros, M., Kwan, A. H., and Trewella, J. (2011) Human cardiac myosin binding protein C: Structural flexibility within an extended modular architecture. *J. Mol. Biol.* 414, 735–748

44. Nadvi, N. A., Michie, K. A., Kwan, A. H., Guss, J. M., and Trewhella, J. (2016) Clinically linked mutations in the central domains of cardiac myosin-binding protein C with distinct phenotypes show differential structural effects. *Structure* 24, 105–115

45. Luther, P. K., Bennett, P. M., Knupp, C., Craig, R., Padron, R., Harris, S. P., Patel, J., and Moss, R. L. (2008) Understanding the organisation and role of myosin binding protein C in normal striated muscle by comparison with MyBP-C knockout cardiac muscle. *J. Mol. Biol.* 384, 60–72

46. Pfuhl, M., and Gautel, M. (2012) Structure, interactions and function of the N-terminus of cardiac myosin binding protein C (MyBP-C): Who does what, with what, and to whom? *J. Muscle Res. Cell Motil.* 33, 83–94

47. Toh, R., Shinohara, M., Takaya, T., Yamashita, T., Masuda, S., Kawashima, S., Yokoyama, M., and Yagi, N. (2006) An X-ray diffraction study on mouse cardiac cross-bridge function in vivo: Effects of adrenergic (beta)-stimulation. *Biophys. J.* 90, 1723–1728

48. Kulikovskaya, I., McClellan, G., Flavigny, J., Carrier, L., and Winegrad, S. (2003) Effect of MyBP-C binding to actin on contractility in heart muscle. *J. Gen. Physiol.* 122, 761–774

49. Shaffer, J. F., and Harris, S. P. (2009) Species-specific differences in the Pro-Ala rich region of cardiac myosin binding protein-C. *J. Muscle Res. Cell Motil.* 30, 303–306

50. Kuster, D. W., Sequeira, V., Najafi, A., Boontje, N. M., Wijinker, P. I., Witjas-Paalberends, E. R., Marston, S. B., Dos Remedios, C. G., Carrier, L., Demmers, J. A., Redwood, C., Sadayappan, S., and van der Velden, J. (2013) GSK3beta phosphorylates newly identified site in the proline-alanine-rich region of cardiac myosin-binding protein C and alters cross-bridge cycling kinetics in human: Short communication. *Circ. Res.* 112, 633–639

51. Sadayappan, S., Gulick, J., Osinska, H., Martin, L. A., Hahn, H. S., Dorn, G. W., 2nd, Klevitsky, R., Seidman, C. E., Seidman, J. G., and Robbins, J. (2005) Cardiac myosin-binding protein-C phosphorylation and cardiac function. *Circ. Res.* 97, 1156–1163

52. Sevrieva, I. R., Brandmeier, B., Ponnam, S., Gautel, M., Irving, M., Campbell, K. S., Sun, Y. B., and Kampourakis, T. (2020) Cardiac myosin regulatory light chain kinase modulates cardiac contractility by phosphorylating both myosin regulatory light chain and troponin I. *J. Biol. Chem.* 295, 4398–4410

53. Kampourakis, T., Ponnam, S., and Irving, M. (2018) Hypertrophic cardiomyopathy mutation R58Q in the myosin regulatory light chain perturbs thick filament-based regulation in cardiac muscle. *J. Mol. Cell Cardiol.* 117, 72–81

54. Michalek, A. J., Howarth, J. W., Gulick, J., Previs, M. J., Robbins, J., Rosevear, P. R., and Warshaw, D. M. (2013) Phosphorylation modulates the mechanical stability of the cardiac myosin-binding protein C motif. *Biophys. J.* 104, 442–452

55. Rohde, J. A., Rooqarine, O., Thomas, D. D., and Muretta, J. M. (2018) Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin. *Proc. Natl. Acad. Sci. U. S. A.* 115, E7486–E7494

56. Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumieny, R., Heer, F. T., de Beer, T. A. P., Rempfer, C., Bordoli, L., Lepore, R., and Schwede, T. (2018) SWISS-MODEL: Homology modeling of protein structures and complexes. *Nucleic Acids Res.* 46, W296–W303

57. Xu, D., and Zhang, Y. (2011) Improving the physical realism and structural accuracy of protein models by a two-step atomic-level energy minimization. *Biophys. J.* 101, 2525–2534

---

cMyBP-C controls cardiac myosin